Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib study of subcutaneous NIZ985 (hetIL-15) with spartalizumab or tislelizumab in CPI-relapsed advanced solid tumors and lymphoma
jRCT2080225081Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of NIZ985 in Non-hematologic malignancy and lymphoma (3 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of NIZ985 alone and in combination with spartalizumab or tislelizumab and Recommended dose for expansion (RDE) of NIZ985. Started Feb 2020; status: completed.
02
Drugs
NIZ985
03
Conditions
Non-hematologic malignancylymphoma
Beyond the preview
Go deeper on jRCT2080225081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225081.